Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 90 entries
Sorted by: Best Match Show Resources per page
Barriers to technology integration in a technology-rich environment

Science education

Schoepp K.
GSID: pejdCTuIE7QJ
K Schoepp - Learning and teaching in higher education: Gulf …, 2005 - emerald.com

This paper reports on one segment of a research project which investigates what faculty members perceive to be acting as barriers in their attempts to integrate [information and …

Cite
Schoepp, K. (2005). Barriers to technology integration in a technology-rich environment. Learning and teaching in higher education: Gulf perspectives, 2(1), 56-79.
Schoepp, Kevin. "Barriers to technology integration in a technology-rich environment." Learning and teaching in higher education: Gulf perspectives 2.1 (2005): 56-79.
Copy Download .nbib Format: MLA
[Rifaximin treatment in hepatic encephalopathy].

Zeitschrift fur Gastroenterologie

Gundling F, Schepp W.
PMID: 21887667
Z Gastroenterol. 2011 Sep;49(9):1345-6. doi: 10.1055/s-0031-1273395. Epub 2011 Sep 01.

No abstract available.

Cite
Gundling F, Schepp W. Rifaximin in der Remissionserhaltung der hepatischen Enzephalopathie bei Leberzirrhose. [Rifaximin treatment in hepatic encephalopathy]. Z Gastroenterol. 2011;49(9):1345-6doi: 10.1055/s-0031-1273395.
Gundling, F., & Schepp, W. (2011). Rifaximin in der Remissionserhaltung der hepatischen Enzephalopathie bei Leberzirrhose. [Rifaximin treatment in hepatic encephalopathy]. Zeitschrift fur Gastroenterologie, 49(9), 1345-6. https://doi.org/10.1055/s-0031-1273395
Gundling, F, and Schepp, W. "Rifaximin in der Remissionserhaltung der hepatischen Enzephalopathie bei Leberzirrhose." [Rifaximin treatment in hepatic encephalopathy]. Zeitschrift fur Gastroenterologie vol. 49,9 (2011): 1345-6. doi: https://doi.org/10.1055/s-0031-1273395
Gundling F, Schepp W. Rifaximin in der Remissionserhaltung der hepatischen Enzephalopathie bei Leberzirrhose. [Rifaximin treatment in hepatic encephalopathy]. Z Gastroenterol. 2011 Sep;49(9):1345-6. doi: 10.1055/s-0031-1273395. Epub 2011 Sep 01. German. PMID: 21887667.
Copy Download .nbib Format: NLM
14 Years after Discovery: Clinical Follow-up on 15 Patients with Inducible Co-Stimulator Deficiency.

Frontiers in immunology

Schepp J, Chou J, Skrabl-Baumgartner A, Arkwright PD, Engelhardt KR, Hambleton S, Morio T, Röther E, Warnatz K, Geha R, Grimbacher B.
PMID: 28861081
Front Immunol. 2017 Aug 16;8:964. doi: 10.3389/fimmu.2017.00964. eCollection 2017.

BACKGROUND: Inducible co-stimulator (ICOS) deficiency was the first monogenic defect reported to cause common variable immunodeficiency (CVID)-like disease in 2003. Since then, 16 patients have been reported worldwide with an increasing range of clinical phenotypes.OBJECTIVE: We sought to compare...

Cite
Schepp J, Chou J, Skrabl-Baumgartner A, et al. 14 Years after Discovery: Clinical Follow-up on 15 Patients with Inducible Co-Stimulator Deficiency. Front Immunol. 2017;8:964doi: 10.3389/fimmu.2017.00964.
Schepp, J., Chou, J., Skrabl-Baumgartner, A., Arkwright, P. D., Engelhardt, K. R., Hambleton, S., Morio, T., Röther, E., Warnatz, K., Geha, R., & Grimbacher, B. (2017). 14 Years after Discovery: Clinical Follow-up on 15 Patients with Inducible Co-Stimulator Deficiency. Frontiers in immunology, 8964. https://doi.org/10.3389/fimmu.2017.00964
Schepp, Johanna, et al. "14 Years after Discovery: Clinical Follow-up on 15 Patients with Inducible Co-Stimulator Deficiency." Frontiers in immunology vol. 8 (2017): 964. doi: https://doi.org/10.3389/fimmu.2017.00964
Schepp J, Chou J, Skrabl-Baumgartner A, Arkwright PD, Engelhardt KR, Hambleton S, Morio T, Röther E, Warnatz K, Geha R, Grimbacher B. 14 Years after Discovery: Clinical Follow-up on 15 Patients with Inducible Co-Stimulator Deficiency. Front Immunol. 2017 Aug 16;8:964. doi: 10.3389/fimmu.2017.00964. eCollection 2017. PMID: 28861081; PMCID: PMC5561331.
Copy Download .nbib Format: NLM
Lithium Diffusion Pathway in Li(1.3)Al(0.3)Ti(1.7)(PO4)3 (LATP) Superionic Conductor.

Inorganic chemistry

Monchak M, Hupfer T, Senyshyn A, Boysen H, Chernyshov D, Hansen T, Schell KG, Bucharsky EC, Hoffmann MJ, Ehrenberg H.
PMID: 26930220
Inorg Chem. 2016 Mar 21;55(6):2941-5. doi: 10.1021/acs.inorgchem.5b02821. Epub 2016 Mar 01.

The Al-substituted LiTi2(PO4)3 powders Li(1+x)Al(x)Ti(2-x)(PO4)3 (LATP) were successfully prepared by a water-based sol-gel process with subsequent calcination and sintering. The crystal structure of obtained samples was characterized at different temperatures using high-resolution synchrotron-based X-ray and neutron powder diffraction. Possible...

Cite
Monchak M, Hupfer T, Senyshyn A, et al. Lithium Diffusion Pathway in Li(1.3)Al(0.3)Ti(1.7)(PO4)3 (LATP) Superionic Conductor. Inorg Chem. 2016;55(6):2941-5doi: 10.1021/acs.inorgchem.5b02821.
Monchak, M., Hupfer, T., Senyshyn, A., Boysen, H., Chernyshov, D., Hansen, T., Schell, K. G., Bucharsky, E. C., Hoffmann, M. J., & Ehrenberg, H. (2016). Lithium Diffusion Pathway in Li(1.3)Al(0.3)Ti(1.7)(PO4)3 (LATP) Superionic Conductor. Inorganic chemistry, 55(6), 2941-5. https://doi.org/10.1021/acs.inorgchem.5b02821
Monchak, Mykhailo, et al. "Lithium Diffusion Pathway in Li(1.3)Al(0.3)Ti(1.7)(PO4)3 (LATP) Superionic Conductor." Inorganic chemistry vol. 55,6 (2016): 2941-5. doi: https://doi.org/10.1021/acs.inorgchem.5b02821
Monchak M, Hupfer T, Senyshyn A, Boysen H, Chernyshov D, Hansen T, Schell KG, Bucharsky EC, Hoffmann MJ, Ehrenberg H. Lithium Diffusion Pathway in Li(1.3)Al(0.3)Ti(1.7)(PO4)3 (LATP) Superionic Conductor. Inorg Chem. 2016 Mar 21;55(6):2941-5. doi: 10.1021/acs.inorgchem.5b02821. Epub 2016 Mar 01. PMID: 26930220.
Copy Download .nbib Format: NLM
Terrestrial arthropods of Steel Creek, Buffalo National River, Arkansas. I. Select beetles (Coleoptera: Buprestidae, Carabidae, Cerambycidae, Curculionoidea excluding Scolytinae).

Biodiversity data journal

Skvarla MJ, Fisher DM, Schnepp KE, Dowling AP.
PMID: 26752967
Biodivers Data J. 2015 Dec 10;(3):e6832. doi: 10.3897/BDJ.3.e6832. eCollection 2015.

BACKGROUND: The Ozark Mountains are a region with high endemism and biodiversity, yet few invertebrate inventories have been made and few sites extensively studied. We surveyed a site near Steel Creek Campground, along the Buffalo National River in Arkansas,...

Cite
Skvarla MJ, Fisher DM, Schnepp KE, et al. Terrestrial arthropods of Steel Creek, Buffalo National River, Arkansas. I. Select beetles (Coleoptera: Buprestidae, Carabidae, Cerambycidae, Curculionoidea excluding Scolytinae). Biodivers Data J. 2015;(3):e6832doi: 10.3897/BDJ.3.e6832.
Skvarla, M. J., Fisher, D. M., Schnepp, K. E., & Dowling, A. P. (2015). Terrestrial arthropods of Steel Creek, Buffalo National River, Arkansas. I. Select beetles (Coleoptera: Buprestidae, Carabidae, Cerambycidae, Curculionoidea excluding Scolytinae). Biodiversity data journal, (3), e6832. https://doi.org/10.3897/BDJ.3.e6832
Skvarla, Michael Joseph, et al. "Terrestrial arthropods of Steel Creek, Buffalo National River, Arkansas. I. Select beetles (Coleoptera: Buprestidae, Carabidae, Cerambycidae, Curculionoidea excluding Scolytinae)." Biodiversity data journal vol. ,3 (2015): e6832. doi: https://doi.org/10.3897/BDJ.3.e6832
Skvarla MJ, Fisher DM, Schnepp KE, Dowling AP. Terrestrial arthropods of Steel Creek, Buffalo National River, Arkansas. I. Select beetles (Coleoptera: Buprestidae, Carabidae, Cerambycidae, Curculionoidea excluding Scolytinae). Biodivers Data J. 2015 Dec 10;(3):e6832. doi: 10.3897/BDJ.3.e6832. eCollection 2015. PMID: 26752967; PMCID: PMC4698462.
Copy Download .nbib Format: NLM
Specialized clinical cytology may improve the results of EUS (endoscopic ultrasound)-guided fine-needle aspiration (FNA) from pancreatic tumors.

Endoscopy international open

Schneider AR, Nerlich A, Topalidis T, Schepp W.
PMID: 26135655
Endosc Int Open. 2015 Apr;3(2):E134-7. doi: 10.1055/s-0034-1390886. Epub 2014 Dec 05.

BACKGROUND AND STUDY AIMS: A variety of factors (needle type, needle passes, tumor location, cytological assessment, etc.) may influence the diagnostic accuracy of endoscopic ultrasound-guided fine-needle aspiration cytology (EUS-FNAC) from pancreatic tumors. Whereas most published studies report a diagnostic...

Cite
Schneider AR, Nerlich A, Topalidis T, et al. Specialized clinical cytology may improve the results of EUS (endoscopic ultrasound)-guided fine-needle aspiration (FNA) from pancreatic tumors. Endosc Int Open. 2014;3(2):E134-7doi: 10.1055/s-0034-1390886.
Schneider, A. R., Nerlich, A., Topalidis, T., & Schepp, W. (2015). Specialized clinical cytology may improve the results of EUS (endoscopic ultrasound)-guided fine-needle aspiration (FNA) from pancreatic tumors. Endoscopy international open, 3(2), E134-7. https://doi.org/10.1055/s-0034-1390886
Schneider, Arne R, et al. "Specialized clinical cytology may improve the results of EUS (endoscopic ultrasound)-guided fine-needle aspiration (FNA) from pancreatic tumors." Endoscopy international open vol. 3,2 (2015): E134-7. doi: https://doi.org/10.1055/s-0034-1390886
Schneider AR, Nerlich A, Topalidis T, Schepp W. Specialized clinical cytology may improve the results of EUS (endoscopic ultrasound)-guided fine-needle aspiration (FNA) from pancreatic tumors. Endosc Int Open. 2015 Apr;3(2):E134-7. doi: 10.1055/s-0034-1390886. Epub 2014 Dec 05. PMID: 26135655; PMCID: PMC4477028.
Copy Download .nbib Format: NLM
Absolute reactivity of halo(pyridyl)carbenes.

The Journal of organic chemistry

Moya-Barrios R, Cozens FL, Schepp NP.
PMID: 19178352
J Org Chem. 2009 Feb 06;74(3):1148-55. doi: 10.1021/jo802132z.

A comprehensive series of halo(pyridyl)carbenes was generated by laser flash photolysis of the appropriate diazirines. Only the chloro- and bromo(2-pyridyl)carbenes and the chloro- and bromo(3-pyridyl)carbenes could be directly observed, but the reactivity of all nine halo(pyridyl)carbenes could be directly...

Cite
Moya-Barrios R, Cozens FL, Schepp NP. Absolute reactivity of halo(pyridyl)carbenes. J Org Chem. 2009;74(3):1148-55doi: 10.1021/jo802132z.
Moya-Barrios, R., Cozens, F. L., & Schepp, N. P. (2009). Absolute reactivity of halo(pyridyl)carbenes. The Journal of organic chemistry, 74(3), 1148-55. https://doi.org/10.1021/jo802132z
Moya-Barrios, Reinaldo, et al. "Absolute reactivity of halo(pyridyl)carbenes." The Journal of organic chemistry vol. 74,3 (2009): 1148-55. doi: https://doi.org/10.1021/jo802132z
Moya-Barrios R, Cozens FL, Schepp NP. Absolute reactivity of halo(pyridyl)carbenes. J Org Chem. 2009 Feb 06;74(3):1148-55. doi: 10.1021/jo802132z. PMID: 19178352.
Copy Download .nbib Format: NLM
[Risk reduction of hepatocellular carcinoma by metformin--time for a change of paradigm?].

Zeitschrift fur Gastroenterologie

Gundling F, Schepp W.
PMID: 22298104
Z Gastroenterol. 2012 Feb;50(2):232-3. doi: 10.1055/s-0031-1281994. Epub 2012 Feb 01.

No abstract available.

Cite
Gundling F, Schepp W. Risikoreduktion des hepatozellulären Karzinoms bei Patienten mit Leberzirrhose und Diabetes mellitus durch Metformin - Zeit für einen Paradigmenwechsel? [Risk reduction of hepatocellular carcinoma by metformin--time for a change of paradigm?]. Z Gastroenterol. 2012;50(2):232-3doi: 10.1055/s-0031-1281994.
Gundling, F., & Schepp, W. (2012). Risikoreduktion des hepatozellulären Karzinoms bei Patienten mit Leberzirrhose und Diabetes mellitus durch Metformin - Zeit für einen Paradigmenwechsel? [Risk reduction of hepatocellular carcinoma by metformin--time for a change of paradigm?]. Zeitschrift fur Gastroenterologie, 50(2), 232-3. https://doi.org/10.1055/s-0031-1281994
Gundling, F, and Schepp, W. "Risikoreduktion des hepatozellulären Karzinoms bei Patienten mit Leberzirrhose und Diabetes mellitus durch Metformin - Zeit für einen Paradigmenwechsel?" [Risk reduction of hepatocellular carcinoma by metformin--time for a change of paradigm?]. Zeitschrift fur Gastroenterologie vol. 50,2 (2012): 232-3. doi: https://doi.org/10.1055/s-0031-1281994
Gundling F, Schepp W. Risikoreduktion des hepatozellulären Karzinoms bei Patienten mit Leberzirrhose und Diabetes mellitus durch Metformin - Zeit für einen Paradigmenwechsel? [Risk reduction of hepatocellular carcinoma by metformin--time for a change of paradigm?]. Z Gastroenterol. 2012 Feb;50(2):232-3. doi: 10.1055/s-0031-1281994. Epub 2012 Feb 01. German. PMID: 22298104.
Copy Download .nbib Format: NLM
Nonhepatic cancer in liver cirrhosis: a retrospective study of prevalence, complication rate after specific oncological treatment, follow-up and prognostic predictors of outcome in 354 patients with cirrhosis.

Anticancer research

Gundling F, Seidl H, Schmidtler F, Löffler N, Strassen I, Wolf P, Pehl C, Schmidt T, Schepp W.
PMID: 21868541
Anticancer Res. 2011 Sep;31(9):2931-8.

BACKGROUND: Nonhepatic cancer risk of cirrhotic patients seems to be increased. Major surgery and chemotherapy in cirrhosis are associated with increased mortality and morbidity, which limits treatment.AIM: The aims of this study were analysis of (a) prevalence, (b) outcome...

Cite
Gundling F, Seidl H, Schmidtler F, et al. Nonhepatic cancer in liver cirrhosis: a retrospective study of prevalence, complication rate after specific oncological treatment, follow-up and prognostic predictors of outcome in 354 patients with cirrhosis. Anticancer Res. 2011;31(9):2931-8
Gundling, F., Seidl, H., Schmidtler, F., Löffler, N., Strassen, I., Wolf, P., Pehl, C., Schmidt, T., & Schepp, W. (2011). Nonhepatic cancer in liver cirrhosis: a retrospective study of prevalence, complication rate after specific oncological treatment, follow-up and prognostic predictors of outcome in 354 patients with cirrhosis. Anticancer research, 31(9), 2931-8.
Gundling, Felix, et al. "Nonhepatic cancer in liver cirrhosis: a retrospective study of prevalence, complication rate after specific oncological treatment, follow-up and prognostic predictors of outcome in 354 patients with cirrhosis." Anticancer research vol. 31,9 (2011): 2931-8.
Gundling F, Seidl H, Schmidtler F, Löffler N, Strassen I, Wolf P, Pehl C, Schmidt T, Schepp W. Nonhepatic cancer in liver cirrhosis: a retrospective study of prevalence, complication rate after specific oncological treatment, follow-up and prognostic predictors of outcome in 354 patients with cirrhosis. Anticancer Res. 2011 Sep;31(9):2931-8. PMID: 21868541.
Copy Download .nbib Format: NLM
Giant Magnetoresistance without Defect Scattering.

Physical review letters

Bauer GE, Kelly PJ, Schep KM.
PMID: 10058795
Phys Rev Lett. 1995 Jan 23;74(4):586-589. doi: 10.1103/PhysRevLett.74.586.

No abstract available.

Cite
Bauer GE, Kelly PJ, Schep KM. Giant Magnetoresistance without Defect Scattering. Phys Rev Lett. 1995;74(4):586-589doi: 10.1103/PhysRevLett.74.586.
Bauer, G. E., Kelly, P. J., & Schep, K. M. (1995). Giant Magnetoresistance without Defect Scattering. Physical review letters, 74(4), 586-589. https://doi.org/10.1103/PhysRevLett.74.586
Bauer, et al. "Giant Magnetoresistance without Defect Scattering." Physical review letters vol. 74,4 (1995): 586-589. doi: https://doi.org/10.1103/PhysRevLett.74.586
Bauer GE, Kelly PJ, Schep KM. Giant Magnetoresistance without Defect Scattering. Phys Rev Lett. 1995 Jan 23;74(4):586-589. doi: 10.1103/PhysRevLett.74.586. PMID: 10058795.
Copy Download .nbib Format: NLM
The University of Missouri Health Care approach to Comprehensive Care for Joint Replacement.

Arthroplasty today

Schelp G.
PMID: 31286035
Arthroplast Today. 2018 Nov 30;5(2):152-153. doi: 10.1016/j.artd.2018.10.006. eCollection 2019 Jun.

The University of Missouri Health Care is a 5-hospital academic medical center with 595 beds, located in the central United States. Our system was selected for mandatory participation in the Comprehensive Care for Joint Replacement bundled payment model and...

Cite
Schelp G. The University of Missouri Health Care approach to Comprehensive Care for Joint Replacement. Arthroplast Today. 2018;5(2):152-153doi: 10.1016/j.artd.2018.10.006.
Schelp, G. (2019). The University of Missouri Health Care approach to Comprehensive Care for Joint Replacement. Arthroplasty today, 5(2), 152-153. https://doi.org/10.1016/j.artd.2018.10.006
Schelp, Ginger. "The University of Missouri Health Care approach to Comprehensive Care for Joint Replacement." Arthroplasty today vol. 5,2 (2019): 152-153. doi: https://doi.org/10.1016/j.artd.2018.10.006
Schelp G. The University of Missouri Health Care approach to Comprehensive Care for Joint Replacement. Arthroplast Today. 2018 Nov 30;5(2):152-153. doi: 10.1016/j.artd.2018.10.006. eCollection 2019 Jun. PMID: 31286035; PMCID: PMC6588682.
Copy Download .nbib Format: NLM
Erratum: Fourier-transform method for accurate analysis of Mössbauer spectra.

Physical review. B, Condensed matter

Cao Y, Cowan D, Crow ML, Djedid A, Mullen JG, Schupp G, Yelon WB.
PMID: 9947221
Phys Rev B Condens Matter. 1989 Jan 01;39(1):753. doi: 10.1103/physrevb.39.753.2.

No abstract available.

Cite
Cao Y, Cowan D, Crow ML, et al. Erratum: Fourier-transform method for accurate analysis of Mössbauer spectra. Phys Rev B Condens Matter. 1989;39(1):753doi: 10.1103/physrevb.39.753.2.
Cao, Y., Cowan, D., Crow, M. L., Djedid, A., Mullen, J. G., Schupp, G., & Yelon, W. B. (1989). Erratum: Fourier-transform method for accurate analysis of Mössbauer spectra. Physical review. B, Condensed matter, 39(1), 753. https://doi.org/10.1103/physrevb.39.753.2
Cao, et al. "Erratum: Fourier-transform method for accurate analysis of Mössbauer spectra." Physical review. B, Condensed matter vol. 39,1 (1989): 753. doi: https://doi.org/10.1103/physrevb.39.753.2
Cao Y, Cowan D, Crow ML, Djedid A, Mullen JG, Schupp G, Yelon WB. Erratum: Fourier-transform method for accurate analysis of Mössbauer spectra. Phys Rev B Condens Matter. 1989 Jan 01;39(1):753. doi: 10.1103/physrevb.39.753.2. PMID: 9947221.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 90 entries